Critical Analysis: Aptevo Therapeutics (APVO) versus BioCryst Pharmaceuticals (BCRX)
Aptevo Therapeutics (NASDAQ: APVO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap bio therapeutic drugs companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.
Insider & Institutional Ownership
32.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 84.7% of BioCryst Pharmaceuticals shares are held by institutional investors. 15.6% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 5.6% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Aptevo Therapeutics and BioCryst Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aptevo Therapeutics||$36.43 million||2.59||-$112.41 million||($1.82)||-2.42|
|BioCryst Pharmaceuticals||$26.35 million||20.43||-$55.14 million||($0.64)||-8.55|
BioCryst Pharmaceuticals has lower revenue, but higher earnings than Aptevo Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Aptevo Therapeutics and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Aptevo Therapeutics and BioCryst Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aptevo Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 36.36%. BioCryst Pharmaceuticals has a consensus price target of $9.14, indicating a potential upside of 67.15%. Given BioCryst Pharmaceuticals’ higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Aptevo Therapeutics.
Aptevo Therapeutics beats BioCryst Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.